Skip to main content
PMC home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1998 Mar;78(2):F133–F137. doi: 10.1136/fn.78.2.f133

Cardiac effects of short course dexamethasone in preterm infants

R Skelton, A Gill, J Parsons
PMCID: PMC1720762  PMID: 9577285

Abstract

AIM—To examine the incidence and natural history of left ventricular hypertrophy (LVH) associated with the shorter 2-3 week course of dexamethasone, now more usual, for chronic lung disease.
METHOD—Thirty one infants, gestational age 23-34 (median 26) weeks, birthweight 500-2054 (median 815)g, received dexamethasone, starting at 0.4-0.6 mg/kg/day, at a median of 11 days of age (range 2-34), weaning over a period of 2-3 weeks. Eighteen preterm neonates were studied as controls over a similar time period. Serial echocardiographic measurements of end diastolic interventricular septum (IVSd) and left ventricular posterior wall (LVPWd) thicknesses were taken before, and up to 48 days after, starting dexamethasone. Maximum Doppler blood flow velocities from the left ventricular outflow tract (LVOT) were measured.
RESULTS—Left ventricular hypertrophy (LVH) occurred in 29 babies (94%). Median hypertrophy of the IVSd in those receiving dexamethasone was 67% and LVPWd 56% of baseline measurements, significantly greater than control infants (p<0.001). LVH appeared by a median of three days, peaking by a median of 10 days. All resolved by a median of 27 days. LVOT obstruction was not seen. There was no significant correlation with birthweight, gestation, blood pressure, or glucose tolerance.
CONCLUSIONS—LVH developed in almost all preterm neonates receiving a 2-3 week course of dexamethasone, but was of little clinical importance and always resolved. Echocardiography is probably not required routinely in infants receiving such short course dexamethasone for chronic lung disease.



Full Text

The Full Text of this article is available as a PDF (104.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bensky A. S., Kothadia J. M., Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics. 1996 Jun;97(6 Pt 1):818–821. [PubMed] [Google Scholar]
  2. Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307–310. [PubMed] [Google Scholar]
  3. Brand P. L., van Lingen R. A., Brus F., Talsma M. D., Elzenga N. J. Hypertrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia. Acta Paediatr. 1993 Jun-Jul;82(6-7):614–617. doi: 10.1111/j.1651-2227.1993.tb12771.x. [DOI] [PubMed] [Google Scholar]
  4. Breitweser J. A., Meyer R. A., Sperling M. A., Tsang R. C., Kaplan S. Cardiac septal hypertrophy in hyperinsulinemic infants. J Pediatr. 1980 Mar;96(3 Pt 2):535–539. doi: 10.1016/s0022-3476(80)80862-6. [DOI] [PubMed] [Google Scholar]
  5. Brownlee K. G., Ng P. C., Henderson M. J., Smith M., Green J. H., Dear P. R. Catabolic effect of dexamethasone in the preterm baby. Arch Dis Child. 1992 Jan;67(1 Spec No):1–4. doi: 10.1136/adc.67.1_spec_no.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carter B. S., DiGiacomo J. E., Balderston S. M., Wiggins J. W., Merenstein G. B. Disproportionate septal hypertrophy associated with erythroblastosis fetalis. Am J Dis Child. 1990 Nov;144(11):1225–1228. doi: 10.1001/archpedi.1990.02150350057024. [DOI] [PubMed] [Google Scholar]
  7. Evans N. Cardiovascular effects of dexamethasone in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 1994 Jan;70(1):F25–F30. doi: 10.1136/fn.70.1.f25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fox L. A., Geffner M. E., al-Khatib Y., Kaplan S. Hyperinsulinemic, hypertrophic cardiomyopathy in infancy. Am J Dis Child. 1992 Aug;146(8):896–898. doi: 10.1001/archpedi.1992.02160200018008. [DOI] [PubMed] [Google Scholar]
  9. Glennon P. E., Sugden P. H., Poole-Wilson P. A. Cellular mechanisms of cardiac hypertrophy. Br Heart J. 1995 Jun;73(6):496–499. doi: 10.1136/hrt.73.6.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Haney I., Lachance C., van Doesburg N. H., Fouron J. C. Reversible steroid-induced hypertrophic cardiomyopathy with left ventricular outflow tract obstruction in two newborns. Am J Perinatol. 1995 Jul;12(4):271–274. doi: 10.1055/s-2007-994472. [DOI] [PubMed] [Google Scholar]
  11. Henry W. L., DeMaria A., Gramiak R., King D. L., Kisslo J. A., Popp R. L., Sahn D. J., Schiller N. B., Tajik A., Teichholz L. E. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-dimensional Echocardiography. Circulation. 1980 Aug;62(2):212–217. doi: 10.1161/01.cir.62.2.212. [DOI] [PubMed] [Google Scholar]
  12. Israel B. A., Sherman F. S., Guthrie R. D. Hypertrophic cardiomyopathy associated with dexamethasone therapy for chronic lung disease in preterm infants. Am J Perinatol. 1993 Jul;10(4):307–310. doi: 10.1055/s-2007-994747. [DOI] [PubMed] [Google Scholar]
  13. Malnick G., Pickoff A. S., Ferrer P. L., Peyser J., Bancalari E., Gelband H. Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia: an echocardiographic and pathologic study. Pediatrics. 1980 Oct;66(4):589–596. [PubMed] [Google Scholar]
  14. Ng P. C. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Arch Dis Child. 1993 Mar;68(3 Spec No):330–336. doi: 10.1136/adc.68.3_spec_no.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ohning B. L., Fyfe D. A., Riedel P. A. Reversible obstructive hypertrophic cardiomyopathy after dexamethasone therapy for bronchopulmonary dysplasia. Am Heart J. 1993 Jan;125(1):253–256. doi: 10.1016/0002-8703(93)90089-r. [DOI] [PubMed] [Google Scholar]
  16. Rajaram S., Carlson S. E., Koo W. W., Rangachari A., Kelly D. P. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 during the first year in term and preterm infants. Pediatr Res. 1995 May;37(5):581–585. doi: 10.1203/00006450-199505000-00004. [DOI] [PubMed] [Google Scholar]
  17. Rosenfeld R. G., Gargosky S. E. Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls. J Pediatr. 1996 May;128(5 Pt 2):S52–S57. doi: 10.1016/s0022-3476(96)70012-4. [DOI] [PubMed] [Google Scholar]
  18. Thorsson A. V., Hintz R. L. Insulin receptors in the newborn. Increase in receptor affinity and number. N Engl J Med. 1977 Oct 27;297(17):908–912. doi: 10.1056/NEJM197710272971704. [DOI] [PubMed] [Google Scholar]
  19. Werner J. C., Sicard R. E., Hansen T. W., Solomon E., Cowett R. M., Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr. 1992 Feb;120(2 Pt 1):286–291. doi: 10.1016/s0022-3476(05)80446-9. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES